Bis-(pyrazolyl-(3))-keton | 20583-35-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Bis-(pyrazolyl-(3))-keton
• 英文别名: bis-(1(2)H-pyrazol-3-yl)-methanone；bis(1H-pyrazol-5-yl)methanone
• CAS: 20583-35-1
• 化学式: C₇H₆N₄O
• 分子量: 162.151
• InChiKey: PJYGPNGTUCHYIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Bis-(pyrazolyl-(3))-keton 、 sodium 3-carboxybenzenesulfonate 在 三乙胺 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 2.0h， 以88.4%的产率得到
  参考文献：
  名称：

  一种泼尼松龙苯酰磺酸钠的制备方法

  摘要：

  本发明提供一种泼尼松龙苯酰磺酸钠的制备方法，包括以下步骤：1)3‑羧基苯磺酸钠与含有氮杂环碳酰化试剂反应生成氮杂酰胺中间体(式Ⅱ)；2)在有机钠盐和N‑卤代酰胺试剂存在下，氮杂酰胺中间体(式Ⅱ)与泼尼松龙反应，得到泼尼松龙苯酰磺酸钠。该反应条件温和，后处理简单，适合于工业化生产，产品质量好，杂质少。

  公开号：

  CN111377995B
• 作为产物：
  描述：

  Bis-[2-(4-methoxy-benzyl)-2H-pyrazol-3-yl]-methanone 在 三氟乙酸 作用下， 反应 16.0h， 以85%的产率得到Bis-(pyrazolyl-(3))-keton
  参考文献：
  名称：

  4-Methoxybenzyl (PMB), A Versatile Protecting Group for the Regiospecific Lithiation and Functionalization of Pyrazoles

  摘要：

  The use of 4-methoxybenzyl (PMB) protecting group for the regiospecific metallation/functionalisation of pyrazole is reported.

  DOI：

  10.1080/00397919508011414

文献信息

• [EN] PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS<br/>[FR] COMPOSÉS PYRAZOLYLE PYRIMIDINONE UTILISÉS EN TANT QU'INHIBITEURS DE PDE2
  申请人：MERCK SHARP & DOHME

  公开号：WO2016154081A1

  公开（公告）日：2016-09-29

  The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及式I的嘧啶甲酰胺化合物，该化合物作为治疗与磷酸二酯酶2（PDE2）相关的中枢神经系统疾病的治疗剂是有用的。本发明还涉及使用这些化合物来治疗神经和精神疾病，如精神分裂症、精神病、帕金森病、帕金森病痴呆（PDD）或亨廷顿病，以及与纹状体功能减退或基底神经节功能障碍相关的疾病。
• PROTEOSTASIS REGULATORS
  申请人：Foley Megan

  公开号：US20120316193A1

  公开（公告）日：2012-12-13

  The present invention is directed to compounds having the Formulae (Ia-Ie), (II), (IIIa-IIId), (IVa-IVc), (Va-Vb), (VIa-VIe), (VII), (VIIIa-VIIIc), and (IX), pharmaceutically acceptable salts, prodrugs and solvates thereof, compositions of any of thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis comprising an effective amount of these compounds.

  本发明涉及具有化学式(Ia-Ie)、(II)、(IIIa-IIId)、(IVa-IVc)、(Va-Vb)、(VIa-VIe)、(VII)、(VIIIa-VIIIc)和(IX)的化合物，以及这些化合物的药用可接受盐、前药和溶剂合物，以及这些化合物的任何组合物，并且用于治疗与蛋白质稳态功能紊乱相关的疾病的方法，包括有效量的这些化合物。
• [EN] OXIDATION OF A PYRAZOLYL KETONE COMPOUND TO THE CORRESPONDING CARBOXYLIC ACID<br/>[FR] OXYDATION D'UN COMPOSÉ DE PYRAZOLYL CÉTONE EN ACIDE CARBOXYLIQUE CORRESPONDANT
  申请人：SOLVAY

  公开号：WO2019110795A1

  公开（公告）日：2019-06-13

  This invention concerns a process for the manufacture of carboxylic acids or carboxylic acid derivatives and a process for the manufacture of agrochemically and pharmaceutically active compounds comprising the process for the manufacture of carboxylic acids or their derivatives. The process for the manufacture of carboxylic acids or carboxylic acid derivatives of formula (II) comprises a step of oxidizing a compound of formula (I) in the presence of at least one compound of formula (III) R6-C(O)O-OH. (I) (II)

  这项发明涉及一种用于制造羧酸或羧酸衍生物的过程，以及一种用于制造农药和药用活性化合物的过程，包括制造羧酸或其衍生物的过程。制造公式（II）的羧酸或羧酸衍生物的过程包括在至少一种公式（III）R6-C（O）O-OH存在的情况下氧化公式（I）的化合物的步骤。
• FUNCTIONALIZED HIGHLY BRANCHED MELAMINE-POLYAMINE POLYMERS
  申请人：Peretolchin Maxim

  公开号：US20120252987A1

  公开（公告）日：2012-10-04

  The present invention relates to a method for producing amphiphilic functionalized highly branched melamine-polyamine polymers by condensing melamine and optionally a melamine derivate having at least one different amine having at least two primary amino groups and optionally also with urea and/or at least one urea derivative and/or with at least one at least difunctional diisocyanate or polyisocyanate and/or at least one carbolic acid having at least two carboxyl groups or at least one derivative thereof, optionally quaternizing a portion of the amino groups of the polymer thereby obtained, reacting the polymer thus obtained with at least one compound capable of undergoing a condensation or addition reaction with amino groups, and optionally quaternizing at least part of the amino groups of the polymer obtained in the first step. The invention further relates to the amphiphilic functionalized highly branched melamine-polyamine polymers that can be obtained by the method according to the invention, and to the use thereof as surface active agents.

  本发明涉及一种通过将三聚氰胺和至少一种具有至少两个主要氨基的不同氨基的三聚氰胺衍生物以及可能还包括尿素和/或至少一种尿素衍生物和/或至少一种至少双官能团二异氰酸酯或多异氰酸酯和/或至少一种至少具有两个羧基的羧酸或其衍生物缩合，从而制备含有两性功能化的高支化三聚氰胺-多胺聚合物的方法。可选地，对所获得的聚合物的部分氨基进行季铵化，然后将所获得的聚合物与至少一种能够与氨基发生缩合或加成反应的化合物反应，并可选地对第一步中获得的聚合物的部分氨基进行季铵化。本发明还涉及通过本发明的方法可以获得的含有两性功能化的高支化三聚氰胺-多胺聚合物，以及将其用作表面活性剂的用途。
• [EN] 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS<br/>[FR] COMPOSÉS 4-(4-PYRIMIDYL)-BENZAMIDES ET UTILISATION DE CEUX-CI COMME MODULATEURS DE L'ACTIVITÉ DE KINASES RHO (ROCK)
  申请人：ABBOTT GMBH & CO KG

  公开号：WO2009027392A1

  公开（公告）日：2009-03-05

  The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs). R1 and R2 are, independently of each other, hydrogen, hydroxy, cyano, C1-C8-alkyl, C1- C8-haloalkyl, C1-C8-alkoxy or C1-C8-haloalkoxy; R3, R4, R5 and R6 are, independently of each other, hydrogen, hydroxy, halogen, cyano, C1-C8-alkyl, C1-C8-haloalkyl, C1-C8-alkoxy, C1-C8-haloalkoxy, amino, C1-C8-alkylamino or di-(C1-C8-alkyl)-amino; R7 is hydrogen, C1-C8-alkyl, C1-C8-haloalkyl, aryl or aryl-C1-C8-alkyl; R8 is a group of the formula -X-W, where X is a single bond, C1-C4-alkylene or C1-C4-alkylene-O-, where the alkylene group in the three last-mentioned radicals may be linear or branched and may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or may be interrupted by an oxygen atom; and W is a cyclic radical selected from phenyl and a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring which contains as ring members 1, 2 or 3 heteroatoms selected from O, S and N and optionally 1 or 2 carbonyl groups; R9 is a group of the formula -Y-Z, where Z is hydrogen, halogen, OR11, NR12R13, S(O)m-R14, phenyl which may carry 1, 2, 3 or 4 substituents R15 or a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring; and Y is linear or branched C1C4-alkylene which may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or a phenyl ring; or, in case Z is phenyl or the 5- or 6-membered heterocyclic ring as defined above, Y can also be a single bond.

  本发明涉及公式（I）的新型4-(4-吡啶基)-苯甲酰胺。化合物I具有有价值的治疗性能，并且特别适用于治疗对Rho激酶（ROCKs）调节产生反应的疾病。R1和R2分别为氢、羟基、氰基、C1-C8-烷基、C1-C8-卤代烷基、C1-C8-烷氧基或C1-C8-卤代烷氧基；R3、R4、R5和R6分别为氢、羟基、卤素、氰基、C1-C8-烷基、C1-C8-卤代烷基、C1-C8-烷氧基、C1-C8-卤代烷氧基、氨基、C1-C8-烷基氨基或二(C1-C8-烷基)-氨基；R7为氢、C1-C8-烷基、C1-C8-卤代烷基、芳基或芳基-C1-C8-烷基；R8为-X-W的基团，其中X为单键、C1-C4-烷基或C1-C4-烷基-O-，在上述最后三个基团中的烷基可以是直链或支链，可以部分或完全卤代，和/或可以被羟基取代，和/或可以被氧原子打断；W为选择自苯基和含有1、2或3个来自O、S和N的杂原子以及可选地包含1或2个羰基的5-或6-成员饱和、部分不饱和或芳香杂环的环基；R9为-Y-Z的基团，其中Z为氢、卤素、OR11、NR12R13、S(O)m-R14、可能携带1、2、3或4个取代基R15的苯基或5-或6-成员饱和、部分不饱和或芳香杂环的环基；Y为线性或支链的C1-C4-烷基，可以部分或完全卤代，和/或可以被羟基取代，和/或可以是苯环；或者，如果Z为苯基或上述定义的5-或6-成员杂环环，Y也可以是单键。